So Ling Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
So Ling Lau has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Liona C. Poon
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR; Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China
4 shared publications - Hillary Hiu Yu Leung
Department of Obstetrics and Gynaecology The Chinese University of Hong Kong Hong Kong SAR China
2 shared publications Iok Seng Wong
Department of Obstetrics and Gynaecology (Y.C., J. Lin, I.S.W., J. Liu, F.L., S.L.L., J.S.Y.W., H.H.Y.L., L.C.P.), The Prince of Wales Hospital, Chinese University of Hong Kong
2 shared publicationsKwong Wai Choy
Department of Obstetrics and Gynaecology The Chinese University of Hong Kong Hong Kong SAR China
2 shared publicationsLo Wong
Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong , Hong Kong SAR
2 shared publications- Nikki M. W. Lee
Department of Obstetrics and Gynecology, Prince of Wales Hospital The Chinese University of Hong Kong Hong Kong SAR China
2 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 174 (2) , 1100-1103
NuViva : Development of postpartum nutrition and exercise program implementing the FIGO pregnancy passport to reduce cardiometabolic risk
Pregnancy provides a unique opportunity to identify women at increased risk of future chronic disease, as adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, gestational diabetes mellitus, preterm birth, placental complications, and fetal growth restriction are associated with later cardiometabolic morbidity. However, postpartum care remains fragmented and limited, representing a missed opportunity for preventive intervention. Currently in pilot phase, NuViva is a novel, multidisciplinary, community‐based postpartum program, providing nutrition, physical exercise, and pelvic floor assessment education at 4 time points over a 12‐month period post delivery. A smartphone application, based on recommendations of the FIGO pregnancy passport, supports biometric record keeping, self‐monitoring, education, and adherence. Assessments include blood pressure and biometrics; laboratory investigations where indicated; pelvic floor assessment; functional fitness tests; and validated psychosocial, lifestyle, and nutrition questionnaires. The primary outcome is cardiovascular health score at 1 year postpartum. Secondary outcomes include anthropometric measures, mental health indicators, reproductive health factors, breastfeeding, physical fitness, and program feasibility metrics such as retention, satisfaction, and resource utilization.
- 20 February 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 174 (2) , 1100-1103
Open AccessNuViva : Development of postpartum nutrition and exercise program implementing the FIGO pregnancy passport to reduce cardiometabolic risk
Pregnancy provides a unique opportunity to identify women at increased risk of future chronic disease, as adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, gestational diabetes mellitus, preterm birth, placental complications, and fetal growth restriction are associated with later cardiometabolic morbidity. However, postpartum care remains fragmented and limited, representing a missed opportunity for preventive intervention. Currently in pilot phase, NuViva is a novel, multidisciplinary, community‐based postpartum program, providing nutrition, physical exercise, and pelvic floor assessment education at 4 time points over a 12‐month period post delivery. A smartphone application, based on recommendations of the FIGO pregnancy passport, supports biometric record keeping, self‐monitoring, education, and adherence. Assessments include blood pressure and biometrics; laboratory investigations where indicated; pelvic floor assessment; functional fitness tests; and validated psychosocial, lifestyle, and nutrition questionnaires. The primary outcome is cardiovascular health score at 1 year postpartum. Secondary outcomes include anthropometric measures, mental health indicators, reproductive health factors, breastfeeding, physical fitness, and program feasibility metrics such as retention, satisfaction, and resource utilization.
- Open Access
- 18 February 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (5-6) , 914-923
NONO ‐Related Syndromic X‐Linked Developmental Disability 34: Further Clinical and Molecular Delineation in a Prenatal Cohort
Objective: To characterize the prenatal sonographic features across different trimesters and genomic spectrum of NONO ‐related X‐linked intellectual developmental disorder. Method: We analyzed two fetuses presenting with corpus callosum agenesis and rare cardiac anomalies using genome sequencing and exome sequencing. A systematic literature review was conducted to provide a comprehensive analysis of genotype‐phenotype correlations. Results: Two novel cases were reported in this study: one with a de novo 61.7 kb deletion affecting both NONO and ITGB1BP2 , and another with a de novo c.1093 C > T(p.Arg365Ter), a recurrent variant reported in the literature. A total of 23 cases with NONO defects and prenatal phenotypes were identified, encompassing 19 distinct variant types. Large deletions and splicing variants accounted for approximately 32% (6/19). Among all cases, 78% (18/23) exhibited typical or concurrent brain abnormalities, such as corpus callosum agenesis, cardiac defects including left ventricular noncompaction (LVNC), or short long bones in the second trimester. Notably, 4% (1/23) of cases were reported with isolated intrauterine growth restriction (IUGR), primarily identified in the third trimester. Conclusion: Genome sequencing facilitates thorough identification of the genetic causes of NONO‐related syndrome. The recurrent variant p.Arg365Ter has been reported to cause variable cardiac abnormalities in different patients, suggesting that other genetic or non‐genetic factors may contribute to the cardiac manifestations in NONO‐related syndromes.
- 18 February 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (5-6) , 914-923
Open AccessNONO ‐Related Syndromic X‐Linked Developmental Disability 34: Further Clinical and Molecular Delineation in a Prenatal Cohort
Objective: To characterize the prenatal sonographic features across different trimesters and genomic spectrum of NONO ‐related X‐linked intellectual developmental disorder. Method: We analyzed two fetuses presenting with corpus callosum agenesis and rare cardiac anomalies using genome sequencing and exome sequencing. A systematic literature review was conducted to provide a comprehensive analysis of genotype‐phenotype correlations. Results: Two novel cases were reported in this study: one with a de novo 61.7 kb deletion affecting both NONO and ITGB1BP2 , and another with a de novo c.1093 C > T(p.Arg365Ter), a recurrent variant reported in the literature. A total of 23 cases with NONO defects and prenatal phenotypes were identified, encompassing 19 distinct variant types. Large deletions and splicing variants accounted for approximately 32% (6/19). Among all cases, 78% (18/23) exhibited typical or concurrent brain abnormalities, such as corpus callosum agenesis, cardiac defects including left ventricular noncompaction (LVNC), or short long bones in the second trimester. Notably, 4% (1/23) of cases were reported with isolated intrauterine growth restriction (IUGR), primarily identified in the third trimester. Conclusion: Genome sequencing facilitates thorough identification of the genetic causes of NONO‐related syndrome. The recurrent variant p.Arg365Ter has been reported to cause variable cardiac abnormalities in different patients, suggesting that other genetic or non‐genetic factors may contribute to the cardiac manifestations in NONO‐related syndromes.
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2)
Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics
BACKGROUND: The effect of parity and previous preeclampsia on the longitudinal maternal hemodynamics during pregnancy has not been studied. METHODS: This was a prospective longitudinal study of maternal hemodynamic profile, assessed by transthoracic echocardiography, for women at 12 +0 to 15 +6 , 20 +0 to 24 +6 , and 30 +0 to 37 +6 weeks of gestation. The study populations were divided into 3 groups: nulliparous women and parous women with and without previous preeclampsia. A linear mixed-effects analysis was performed to compare the longitudinal changes in hemodynamics across gestation among the study groups, controlling for maternal characteristics and medical history in the index pregnancy. RESULTS: Our study involved 760 nulliparous women, 318 parous women without previous preeclampsia, and 59 parous women with previous preeclampsia. The parous with previous preeclampsia group had the highest median mean arterial pressure and systemic vascular resistance compared with the other 2 groups throughout gestation (all P +6 and 30 +0 to 37 +6 weeks. Parous women without previous preeclampsia demonstrated a higher estimated marginal mean of cardiac output and a lower estimated marginal mean of systemic vascular resistance compared with nulliparous women throughout gestation (all P <0.05). CONCLUSIONS: The study has revealed that parous women without previous preeclampsia show optimal cardiovascular responses. In contrast, those with a history of preeclampsia exhibit suboptimal cardiovascular adaptation, and the cardiovascular changes observed from the second trimester in the index pregnancy are attributed to maternal characteristics and the development of preeclampsia.
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2)
Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics
BACKGROUND: The effect of parity and previous preeclampsia on the longitudinal maternal hemodynamics during pregnancy has not been studied. METHODS: This was a prospective longitudinal study of maternal hemodynamic profile, assessed by transthoracic echocardiography, for women at 12 +0 to 15 +6 , 20 +0 to 24 +6 , and 30 +0 to 37 +6 weeks of gestation. The study populations were divided into 3 groups: nulliparous women and parous women with and without previous preeclampsia. A linear mixed-effects analysis was performed to compare the longitudinal changes in hemodynamics across gestation among the study groups, controlling for maternal characteristics and medical history in the index pregnancy. RESULTS: Our study involved 760 nulliparous women, 318 parous women without previous preeclampsia, and 59 parous women with previous preeclampsia. The parous with previous preeclampsia group had the highest median mean arterial pressure and systemic vascular resistance compared with the other 2 groups throughout gestation (all P +6 and 30 +0 to 37 +6 weeks. Parous women without previous preeclampsia demonstrated a higher estimated marginal mean of cardiac output and a lower estimated marginal mean of systemic vascular resistance compared with nulliparous women throughout gestation (all P <0.05). CONCLUSIONS: The study has revealed that parous women without previous preeclampsia show optimal cardiovascular responses. In contrast, those with a history of preeclampsia exhibit suboptimal cardiovascular adaptation, and the cardiovascular changes observed from the second trimester in the index pregnancy are attributed to maternal characteristics and the development of preeclampsia.
- 3 January 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 71 (1) , 155-168
Mate-Pair Sequencing Enables Identification and Delineation of Balanced and Unbalanced Structural Variants in Prenatal Cytogenomic Diagnostics
Background: Mate-pair sequencing detects both balanced and unbalanced structural variants (SVs) and simultaneously informs in relation to both genomic location and orientation of SVs for enhanced variant classification and clinical interpretation, while chromosomal microarray analysis (CMA) only reports deletion/duplication. Herein, we evaluated its diagnostic utility in a prospective back-to-back prenatal comparative study with CMA. Methods: From October 2021 to September 2023, 426 fetuses with ultrasound anomalies were prospectively recruited for mate-pair sequencing and CMA in parallel for prenatal genetic diagnosis. Balanced/unbalanced SVs and regions with absence of heterozygosity (AOH) were detected and classified independently, and comparisons were made between mate-pair sequencing and CMA to assess concordance. In addition, novel SVs were investigated for potential RNA perturbations using cultured cells, whenever available. Results: Mate-pair sequencing and CMA successfully yielded results for all 426 fetuses without the need for cell culturing. In addition, mate-pair sequencing identified 19 cases with aneuploidies, 16 cases with pathogenic simple deletions/duplications, and 5 cases with pathogenic translocations/insertions, providing a 25% incremental diagnostic yield compared to CMA (9.4%, 40/426 vs 7.6%, 32/426). Furthermore, by identifying the location and orientation of SVs, mate-pair sequencing improved the variant interpretation and/or follow-up approach for 40.0% (12) of the 30 cases with likely clinically significant deletions/duplications reported by CMA. Lastly, both platforms reported 3 cases (3/426) with multiple regions of AOH likely attributable to parental consanguinity. Conclusions: Mate-pair sequencing detects additional balanced/unbalanced SVs and improves variant interpretation in comparison to CMA, indicating its potential to serve as a comprehensive prenatal cytogenomic diagnostic method.
- 3 January 2025
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 71 (1) , 155-168
Mate-Pair Sequencing Enables Identification and Delineation of Balanced and Unbalanced Structural Variants in Prenatal Cytogenomic Diagnostics
Background: Mate-pair sequencing detects both balanced and unbalanced structural variants (SVs) and simultaneously informs in relation to both genomic location and orientation of SVs for enhanced variant classification and clinical interpretation, while chromosomal microarray analysis (CMA) only reports deletion/duplication. Herein, we evaluated its diagnostic utility in a prospective back-to-back prenatal comparative study with CMA. Methods: From October 2021 to September 2023, 426 fetuses with ultrasound anomalies were prospectively recruited for mate-pair sequencing and CMA in parallel for prenatal genetic diagnosis. Balanced/unbalanced SVs and regions with absence of heterozygosity (AOH) were detected and classified independently, and comparisons were made between mate-pair sequencing and CMA to assess concordance. In addition, novel SVs were investigated for potential RNA perturbations using cultured cells, whenever available. Results: Mate-pair sequencing and CMA successfully yielded results for all 426 fetuses without the need for cell culturing. In addition, mate-pair sequencing identified 19 cases with aneuploidies, 16 cases with pathogenic simple deletions/duplications, and 5 cases with pathogenic translocations/insertions, providing a 25% incremental diagnostic yield compared to CMA (9.4%, 40/426 vs 7.6%, 32/426). Furthermore, by identifying the location and orientation of SVs, mate-pair sequencing improved the variant interpretation and/or follow-up approach for 40.0% (12) of the 30 cases with likely clinically significant deletions/duplications reported by CMA. Lastly, both platforms reported 3 cases (3/426) with multiple regions of AOH likely attributable to parental consanguinity. Conclusions: Mate-pair sequencing detects additional balanced/unbalanced SVs and improves variant interpretation in comparison to CMA, indicating its potential to serve as a comprehensive prenatal cytogenomic diagnostic method.
- Top Cited PapersOpen Access
- 15 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (16) , 1223-1235
Implementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.
- 15 October 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (16) , 1223-1235
Top Cited PapersOpen AccessImplementation of First-Trimester Screening and Prevention of Preeclampsia: A Stepped Wedge Cluster-Randomized Trial in Asia
BACKGROUND: This trial aimed to assess the efficacy, acceptability, and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia in Asia. METHODS: Between August 1, 2019, and February 28, 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from 10 regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular 6-week intervals, one cluster was randomized to transit from nonintervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm preeclampsia using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm preeclampsia ≥1 in 100, received low-dose aspirin from <16 weeks until 36 weeks. RESULTS: Overall, 88.04% (42 897 of 48 725) of women agreed to undergo first-trimester screening for preterm preeclampsia. Among those identified as high-risk in the intervention phase, 82.39% (2919 of 3543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm preeclampsia between the intervention and non-intervention phases (adjusted odds ratio [aOR], 1.59 [95% CI, 0.91–2.77]). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm preeclampsia (aOR, 0.59 [95% CI, 0.37–0.92]). In addition, it correlated with 54%, 55%, and 64% reduction in the incidence of preeclampsia with delivery at <34 weeks (aOR, 0.46 [95% CI, 0.23–0.93]), spontaneous preterm birth <34 weeks (aOR, 0.45 [95% CI, 0.22–0.92]), and perinatal death (aOR, 0.34 [95% CI, 0.12–0.91]), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events. CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm preeclampsia is not associated with a significant reduction in the incidence of preterm preeclampsia. However, low-dose aspirin effectively reduces the incidence of preterm preeclampsia by 41% among high-risk women. The screen-and-prevent strategy for preterm preeclampsia is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm preeclampsia on a global scale. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03941886.
- Open Access
- 29 August 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (11) , 1355-1365
Methylation-Associated Nucleosomal Patterns of Cell-Free DNA in Cancer Patients and Pregnant Women
Cell-free DNA (cfDNA) analysis offers an attractive noninvasive means of detecting and monitoring diseases. cfDNA cleavage patterns within a short range (e.g., 11 nucleotides) have been reported to correlate with cytosine-phosphate-guanine (CpG) methylation, allowing fragmentomics-based methylation analysis (FRAGMA). Here, we adopted FRAGMA to the extended region harboring multiple nucleosomes, termed FRAGMAXR. We profiled cfDNA nucleosomal patterns over the genomic regions from −800 to 800 bp surrounding differentially methylated CpG sites, harboring approximately 8 nucleosomes, referred to as CpG-associated cfDNA nucleosomal patterns. Such nucleosomal patterns were analyzed by FRAGMAXR in cancer patients and pregnant women. We identified distinct cfDNA nucleosomal patterns around differentially methylated CpG sites. Compared with subjects without cancer, patients with hepatocellular carcinoma (HCC) showed reduced amplitude of nucleosomal patterns, with a gradual decrease over tumor stages. Nucleosomal patterns associated with differentially methylated CpG sites could be used to train a machine learning model, resulting in the detection of HCC patients with an area under the receiver operating characteristic curve of 0.93. We further demonstrated the feasibility of multicancer detection using a dataset comprising lung, breast, and ovarian cancers. The tissue-of-origin analysis of plasma cfDNA from pregnant women and cancer patients revealed that the placental DNA and tumoral DNA contributions deduced by FRAGMAXR correlated well with values measured using genetic variants (Pearson r: 0.85 and 0.94, respectively). CpG-associated cfDNA nucleosomal patterns of cfDNA molecules are influenced by DNA methylation and might be useful for biomarker developments for cancer liquid biopsy and noninvasive prenatal testing.
- 29 August 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (11) , 1355-1365
Open AccessMethylation-Associated Nucleosomal Patterns of Cell-Free DNA in Cancer Patients and Pregnant Women
Cell-free DNA (cfDNA) analysis offers an attractive noninvasive means of detecting and monitoring diseases. cfDNA cleavage patterns within a short range (e.g., 11 nucleotides) have been reported to correlate with cytosine-phosphate-guanine (CpG) methylation, allowing fragmentomics-based methylation analysis (FRAGMA). Here, we adopted FRAGMA to the extended region harboring multiple nucleosomes, termed FRAGMAXR. We profiled cfDNA nucleosomal patterns over the genomic regions from −800 to 800 bp surrounding differentially methylated CpG sites, harboring approximately 8 nucleosomes, referred to as CpG-associated cfDNA nucleosomal patterns. Such nucleosomal patterns were analyzed by FRAGMAXR in cancer patients and pregnant women. We identified distinct cfDNA nucleosomal patterns around differentially methylated CpG sites. Compared with subjects without cancer, patients with hepatocellular carcinoma (HCC) showed reduced amplitude of nucleosomal patterns, with a gradual decrease over tumor stages. Nucleosomal patterns associated with differentially methylated CpG sites could be used to train a machine learning model, resulting in the detection of HCC patients with an area under the receiver operating characteristic curve of 0.93. We further demonstrated the feasibility of multicancer detection using a dataset comprising lung, breast, and ovarian cancers. The tissue-of-origin analysis of plasma cfDNA from pregnant women and cancer patients revealed that the placental DNA and tumoral DNA contributions deduced by FRAGMAXR correlated well with values measured using genetic variants (Pearson r: 0.85 and 0.94, respectively). CpG-associated cfDNA nucleosomal patterns of cfDNA molecules are influenced by DNA methylation and might be useful for biomarker developments for cancer liquid biopsy and noninvasive prenatal testing.
- 13 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 176-184
Gestational Age-specific Reference Intervals for Androgens in Pregnancy
Background Androgen could impact cervical remodelling during pregnancy, and a higher level is associated with adverse pregnancy outcomes. A population-based gestation age-specific reference interval (RI) of total testosterone (TT), androstenedione (A4), and 17-hydroxyprogesterone (17-OHP) can help to diagnose maternal hyperandrogenism. Methods We enrolled 600 healthy Chinese women to obtain longitudinal serum samples across gestation. The serum androgen profile was measured by liquid chromatography-tandem mass spectrometry. The equations for medians of TT, A4, and 17-OHP were generated by MedCal, and the variances adjusted for 2-level modeling were generated by MLwiN, a system for the specification and analysis of a range of multilevel models. Results A4 and TT levels increased across the gestation, and they closely correlated with each other (R = 0.90, P=th gestational week to 16th gestational week and then increased afterward towards the end of pregnancy. Women diagnosed with preeclampsia (PE) were found to have a significantly higher level of A4, TT, and 17-OHP when compared with non-PE cases with p ≤0.01, whereas mothers carrying male versus female fetuses have comparable levels of A4, TT, and 17-OHP. Conclusion The study highlights a methodology for constructing gestational age-specific TT, A4, and 17-OHP levels to provide a better interpretation of results in a cohort of healthy Chinese women. The observation in PE supports previous findings, and the higher levels of TT, A4, and 17-OHP were observed before the onset of PE.
- 13 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 176-184
Gestational Age-specific Reference Intervals for Androgens in Pregnancy
Background Androgen could impact cervical remodelling during pregnancy, and a higher level is associated with adverse pregnancy outcomes. A population-based gestation age-specific reference interval (RI) of total testosterone (TT), androstenedione (A4), and 17-hydroxyprogesterone (17-OHP) can help to diagnose maternal hyperandrogenism. Methods We enrolled 600 healthy Chinese women to obtain longitudinal serum samples across gestation. The serum androgen profile was measured by liquid chromatography-tandem mass spectrometry. The equations for medians of TT, A4, and 17-OHP were generated by MedCal, and the variances adjusted for 2-level modeling were generated by MLwiN, a system for the specification and analysis of a range of multilevel models. Results A4 and TT levels increased across the gestation, and they closely correlated with each other (R = 0.90, P=th gestational week to 16th gestational week and then increased afterward towards the end of pregnancy. Women diagnosed with preeclampsia (PE) were found to have a significantly higher level of A4, TT, and 17-OHP when compared with non-PE cases with p ≤0.01, whereas mothers carrying male versus female fetuses have comparable levels of A4, TT, and 17-OHP. Conclusion The study highlights a methodology for constructing gestational age-specific TT, A4, and 17-OHP levels to provide a better interpretation of results in a cohort of healthy Chinese women. The observation in PE supports previous findings, and the higher levels of TT, A4, and 17-OHP were observed before the onset of PE.
- Open Access
- 12 December 2022
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 102 (2) , 174-180
Neonatal outcome of infants with umbilical cord arterial pH less than 7
Introduction: Umbilical arterial pH of less than 7 is often used as the threshold below which the risks of neonatal death and adverse long‐term neurological outcomes are considered to be higher. Yet within the group with pH p < 0.001), lower cord arterial base excess (−19.95 vs −15.90 mmol/L, p < 0.001), a higher proportion of having AS at 5 min p < 0.001), and a higher proportion of having a sentinel event (34.6% vs 16.7%, p = 0.034). Multivariate analysis confirmed cord arterial pH of <6.9 and an Apgar score at 5 min <7 as independent prognostic factors (the adjusted odds ratios were 4.64 and 6.62, respectively). The risk of adverse outcome increased from 4.3% when the arterial pH was between 6.9 and <7, to 30% when the pH was <6.9.Conclusions: Infants born with umbilical artery pH <7 still have a high chance of 89.5% to become intact survivors. A cord arterial pH of <6.9 and an Apgar score at 5 min <7 are independent prognostic factors for neonatal/infant death or adverse long‐term neurological outcomes.
- 12 December 2022
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 102 (2) , 174-180
Open AccessNeonatal outcome of infants with umbilical cord arterial pH less than 7
Introduction: Umbilical arterial pH of less than 7 is often used as the threshold below which the risks of neonatal death and adverse long‐term neurological outcomes are considered to be higher. Yet within the group with pH p < 0.001), lower cord arterial base excess (−19.95 vs −15.90 mmol/L, p < 0.001), a higher proportion of having AS at 5 min p < 0.001), and a higher proportion of having a sentinel event (34.6% vs 16.7%, p = 0.034). Multivariate analysis confirmed cord arterial pH of <6.9 and an Apgar score at 5 min <7 as independent prognostic factors (the adjusted odds ratios were 4.64 and 6.62, respectively). The risk of adverse outcome increased from 4.3% when the arterial pH was between 6.9 and <7, to 30% when the pH was <6.9.Conclusions: Infants born with umbilical artery pH <7 still have a high chance of 89.5% to become intact survivors. A cord arterial pH of <6.9 and an Apgar score at 5 min <7 are independent prognostic factors for neonatal/infant death or adverse long‐term neurological outcomes.
- 21 May 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 227 (4) , 627.e1-627.e23
Dynamic changes in maternal immune biomarkers during labor in nulliparous vs multiparous women
- 21 May 2022
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 227 (4) , 627.e1-627.e23
Dynamic changes in maternal immune biomarkers during labor in nulliparous vs multiparous women